Spotlight On... Novartis settlement with U.S. SEC on China bribes one in a string; Takara Bio in CAR-T pact with Cellectis; Shanghai Pharma raises funds for online venture; and more...

Swiss-based Novartis ($NVS) has paid the U.S. SEC $25 million to settle civil charges it bribed medical personnel in China to boost drug sales during the decade from 2003 to 2013. The settlement follows a March decision by Bristol-Myers Squibb ($BMY) to stop direct-to-doctor sales support activities in China after it was fined $14.7 million in October last year to settle a case under the Foreign Corrupt Practices Act for providing cash incentives and gifts to promote China sales. As well, in February China-focused SciClone Pharmaceuticals ($SCLN) settled a similar case for $12.8 million. The string of settlements also points to how companies, led by GlaxoSmithKline ($GSK) that paid a $489 million fine in China in 2014 on bribery charges, are reassessing drug sale methods in China as the country pursues its own corruption crackdown. Last year for example, China moved to scrap a markup on drugs by state hospitals that used the earnings to fund operations--and which provided an incentive for doctors to write prescriptions. More from FiercePharma

> Otsu, Japan-based Takara Bio will work with Nasdaq-listed CAR-T immunotherapies developer Cellectis ($CLLS) to manufacture recombinant human fibronectin fragment. Terms were not disclosed. Release

> Shanghai Pharmaceuticals reported net profits up 11% in 2015 at RMB2.9 billion ($448 million) as the firm moves to raise up to RMB5 billion in debt to fund expansion plans. Separately, the firm raised RMB125 million ($21 million) in a Series A+ round for its online pharmaceutical effort Shanghai Pharmaceutical Big Health Yunshang from Softbank China Venture Capital and the Shanghai Charity Foundation. Release

> India has stopped the need for repeat tests of drugs on animals by amending its Drugs and Cosmetic Act. Report

> Tokyo-based drug firm Eisai has sold U.S. rights for Akynzeo, used to treat chemotherapy-induced nausea, to the U.S. unit of Helsinn Therapeutics of Lugano, Switzerland. Both firms will continue to co-promote Aloxi (palonosetron HCl) injection in the U.S. for the same need. Release

> Doctors in China's Jilin province performed a successful surgery using a 3D-printed heart model on a 9-month-old baby suffering from a severe congenital heart defect, state-run news agency Xinhua said, adding the country's first such procedure was performed in July 2015 in Jiangsu Province. Report